This roundtable series explores the use of later-line therapies in patients with diffuse large B-cell lymphoma discussed in virtual live events.
Part 2: Shah Discusses Challenges in Using Lenalidomide Plus Tafasitamab for Patients With DLBCL
October 28th 2021Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.
Part 3: Polatuzumab Vedotin Plus Bendamustine and Rituximab Shows Promise in Patients With DLBCL
November 1st 2021The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.
Part 3: Kline Discusses the Use of Tafasitamab in Certain Patients with R/R DLBCL
November 16th 2021While antibody-drug conjugates have shown promise in patients with relapsed/refractory diffuse large B-cell lymphoma, there are other options that can help patients before moving on to CAR T-cell therapy.
Part 3: Third-Line Use of Loncastuximab for Relapsed/Refractory DLBCL
December 6th 2021During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.
Part 2: Loncastuximab as a Third-Line Therapy for Relapsed/Refractory DLBCL
December 15th 2021During a live virtual event, Paolo Caimi, MD, discussed the toxicity and dosage of loncastuximab tesirine as a third-line therapy for diffuse large B-cell lymphoma before receiving chimeric antigen receptor T-cell therapy.
Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL
June 6th 2022During a live virtual event, Jason Westin, MD, discussed with participants the choice of third-line treatment for relapsed/refractory diffuse large B-cell lymphoma for a patient who declines chimeric antigen receptor T-cell therapy.
Efficacy Data Support Loncastuximab as Third-Line DLBCL Treatment
June 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed the data supporting the safety and efficacy of loncastuximab tesirine in patients with diffuse large B-cell lymphoma. This is the first of 2 articles based on this event.
Physicians Discuss Roles of Later-Line Therapies in DLBCL
July 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed with oncologists how they use loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma.
Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL
July 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the choice of treatment options for a patient with relapsed/refractory diffuse large B-cell lymphoma who previously received R-CHOP and pola-BR.
Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL
August 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the role of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mehdi H. Hamadani, MD, discussed the efficacy of therapies for diffuse large B-cell lymphoma after progression on chimeric antigen receptor T-cell therapy. This is the first of 2 articles based on this event.
Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL
October 2nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Medhi H. Hamadani, MD, discussed the bispecific T-cell engagers epcoritamab and glofitamab and how they fit into the treatment algorithm for patients with diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Bispecific Agents Vs Loncastuximab as Third-Line Therapy for R/R DLBCL
January 5th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Paolo Strati, MD, discussed treatment selection and sequencing of loncastuximab in the context of new bispecific T-cell engagers. This is the second of 2 articles based on this event.
ADC Loncastuximab Shows Signs of Durable Response in R/R DLBCL
January 10th 2024In the first part of a 2-article series, Matthew Matasar, MD, MS, discusses where loncastuximab fits into the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and the data that led to the antibody drug conjugate’s approval.
Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL
February 7th 2024In the second part of a 2-article series, Matthew Matasar, MD, MS, discusses long-term follow up data from the LOTIS-2 trial and how these data show the durability and tolerability of loncastuximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.